Market stability is an evolutionary process where each crisis acts as a learning event. The 2008 crash taught policymakers how to respond with tools like credit facilities, enabling a much faster, more effective response to the COVID-19 shock. Crises are not just failures but necessary reps that improve systemic resilience.

Success in community bank investing doesn't require complex esoteric analysis. It boils down to four key metrics: high capital levels (equity-to-assets), low non-performing assets (under 2%), stable or growing book value, and a low price-to-tangible book value (under 85%).

Intrinsic value shouldn't be confused with a 12-month price target. It is a calculation of a company's long-term worth, akin to a private market or takeover value. This stable anchor allows investors to assess the "margin of safety" at any given market price and ignore daily noise, rather than chasing a specific trading level.

Before concluding a company can sustain extraordinary growth, consult historical data ('base rates') on how many similar companies succeeded in the past. This 'outside view,' a concept from investor Michael Mauboussin, provides a crucial reality check against overly optimistic forecasts.

Judging investment skill requires observing performance through both bull and bear markets. A fixed period, like 5 or 10 years, can be misleading if it only captures one type of environment, often rewarding mere risk tolerance rather than genuine ability.

During profound economic instability, the winning strategy isn't chasing the highest returns, but rather avoiding catastrophic loss. The greatest risks are not missed upside, but holding only cash as inflation erodes its value or relying solely on a paycheck.

Anchoring valuation on a company's typical price-to-sales ratio helps identify buying opportunities when margins are temporarily depressed. This avoids the pitfalls of methods like the Magic Formula, which can mistakenly favor companies at their cyclical earnings peaks, leading to underperformance.

Average drawdown is superior to metrics like standard deviation because it measures both the magnitude and duration of a portfolio's decline. This combination better reflects the actual emotional discomfort clients experience during a market downturn, making it a more practical gauge of risk.

While biotech seems exceptionally volatile, data shows its average 60% annual peak-to-trough drawdown isn't dramatically worse than the ~50% for typical non-biopharma small caps. The perceived risk is disproportionate to the actual incremental volatility required for potentially asymmetric returns.